Clinical trials: Chondrosarcoma
- Condition Chondrosarcoma
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ewing Sarcoma, Myxoid Liposarcoma
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Single agent, non-randomized, open label expansion in select sarcoma patients including myxoid liposarcoma and other sarcomas that share similar chromosomal translocations to Ewing sarcoma; AND dose expansion of the combination…
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor
- Trial name
- NCT03600649
- Testing
- Seclidemstat, Cyclophosphamide, Topotecan
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Ewing Sarcoma, Myxoid Liposarcoma
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.
- Conditions
- Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma
- Trial name
- NCT05266196
- Testing
- Seclidemstat
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Chondrosarcomas, Alveolar Soft Part Sarcomas
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
This is a phase II study of perifosine in patients with chondrosarcomas, alveolar soft part sarcomas and extra-skeletal myxoid chondrosarcomas.
- Conditions
- Chondrosarcomas, Alveolar Soft Part Sarcomas, Extra Skeletal Myxoid Chondrosarcomas
- Trial name
- NCT00401388
- Testing
- Perifosine, Loperamide, Allopurinol
- Volunteers
- 72 people
- Sponsor
- AEterna Zentaris
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma, Ewing, Chondrosarcoma
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body.
- Conditions
- Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
- Trial name
- NCT06387485
- Testing
- 3D Printed Anatomic Model, CT/MRI
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ricoh USA, Inc.